GlassScriptPhysician profile
James H Frank
NPI 1669436143
$3,949.58
in general payments reported to CMS, 2019-2025
19 companies · $657 in 2025
The $657 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $255 · 2021: $465 · 2022: $742 · 2023: $813 · 2024: $475 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,944.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,467.59 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $1,223.30 | 2019-2025 | Vabysmo, Lucentis |
| Novartis Pharmaceuticals Corporation | $278.21 | 2019-2023 | |
| Allergan, INC. | $278.08 | 2019-2021 | |
| Alimera Sciences, INC. | $191.59 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $86.27 | 2022-2024 | Xiidra |
| Mallinckrodt Hospital Products INC. | $70.08 | 2020-2024 | Acthar |
| Harrow Eye, LLC | $54.65 | 2024-2025 | Iheezo, Vevye |
| Tarsus Pharmaceuticals, INC. | $43.03 | 2025 | Xdemvy |
| Coherus Oncology, INC. | $42.82 | 2022-2023 | |
| Apellis Pharmaceuticals, INC. | $39.15 | 2023 | Syfovre |
| Lkc Technologies, INC. | $34.22 | 2023 | |
| Dutch Ophthalmic, USA | $25.12 | 2024 | Eva, Combined Machine, Tissueblue |
| Ocular Therapeutix, INC. | $24.83 | 2019 | |
| Amgen INC. | $24.51 | 2025 | Tepezza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $21.84 | 2023 | |
| Eyepoint US, INC. | $20.84 | 2019 | |
| US Oncology Corporate, INC. | $11.77 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $11.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Frank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.